HF
FATE icon

HRT Financial’s Fate Therapeutics FATE Stock Holding History

HRT Financial’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12K Sell
10,398
-38,146
-79% -$46.4K ﹤0.01% 3619
2025
Q4 		$47K Sell
48,544
-12,333
-20% -$14.8K ﹤0.01% 2881
2025
Q3 		$76K Buy
+60,877
New +$65.6K ﹤0.01% 2554
2025
Q1 		– Sell
-29,173
Closed -$48K – 2757
2024
Q4 		$48K Sell
29,173
-179,971
-86% -$453K ﹤0.01% 2114
2024
Q3 		$732K Buy
209,144
+150,118
+254% +$584K ﹤0.01% 1406
2024
Q2 		$193K Buy
+59,026
New +$258K ﹤0.01% 1672
2024
Q1 		– Sell
-395,753
Closed -$1.48M – 2539
2023
Q4 		$1.48M Sell
395,753
-277,537
-41% -$655K 0.01% 797
2023
Q3 		$1.43M Buy
673,290
+411,679
+157% +$1.36M 0.01% 789
2023
Q2 		$1.25M Buy
+261,611
New +$1.44M 0.01% 816
2023
Q1 		– Sell
-37,915
Closed -$382K – 2691
2022
Q4 		$382K Sell
37,915
-68,210
-64% -$1.28M 0.01% 1594
2022
Q3 		$2.38M Buy
+106,125
New +$3.07M 0.03% 543
2021
Q4 		– Sell
-56,876
Closed -$3.37M – 3442
2021
Q3 		$3.37M Sell
56,876
-57,067
-50% -$4.48M 0.02% 467
2021
Q2 		$9.89M Buy
+113,943
New +$9.18M 0.09% 186
2021
Q1 		– Sell
-16,241
Closed -$1.48M – 2822
2020
Q4 		$1.48M Buy
+16,241
New +$1.01M 0.03% 438
2019
Q4 		– Sell
-28,603
Closed -$444K – 1300
2019
Q3 		$444K Buy
+28,603
New +$548K 0.02% 737
2018
Q4 		– Sell
-35,845
Closed -$583K – 637
2018
Q3 		$583K Buy
+35,845
New +$424K 0.09% 158

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HRT Financial's FATE Position: Q1 2026 in Review

HRT Financial reduced its Fate Therapeutics (FATE) stake by 79% in Q1 2026, selling an estimated $46.4K and leaving 10,398 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #3619.

HRT Financial first reported a position in FATE in Q3 2018 and has held it in 16 quarters since. The position peaked at $9.89M in Q2 2021. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • HRT Financial held 10,398 shares of Fate Therapeutics worth $12K as of Q1 2026.
  • HRT Financial sold 38,146 Fate Therapeutics shares in Q1 2026, an estimated $46.4K.
  • Fate Therapeutics made up ﹤0.01% of HRT Financial's portfolio in Q1 2026, its #3619 holding.
  • HRT Financial first reported a position in Fate Therapeutics in Q3 2018 and has held it in 16 quarters since.
  • HRT Financial's Fate Therapeutics position peaked at $9.89M in Q2 2021.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.